Mammary Cell News Volume 8.13 | Apr 7 2016

FOXC1 Is Involved in ERα Silencing by Counteracting GATA3 Binding and Is Implicated in Endocrine Resistance
Researchers demonstrated a novel FOXC1-driven mechanism that suppresses ERα expression in breast cancer. They found that FOXC1 competes with GATA-binding protein 3 (GATA3) for the same binding regions in the cis-regulatory elements upstream of the ERα gene and thereby downregulates ERα expression and consequently its transcriptional activity. [Oncogene] Abstract

The Heparan Sulfate Sulfotransferase 3-OST3A (HS3ST3A) Is a Novel Tumor Regulator and a Prognostic Marker in Breast Cancer
Investigators report a novel cellular and pathophysiological significance for HS3ST3A, catalyzing the final maturation step of heparan sulfate, in breast cancer. [Oncogene] Abstract

ERRα Regulated Lactate Metabolism Contributes to Resistance to Targeted Therapies in Breast Cancer
The authors find that some breast cancer cells can switch to utilizing lactate as a primary source of energy, allowing them to survive glucose deprivation for extended periods, and that this activity confers resistance to PI3K/mTOR inhibitors. [Cell Rep] Full Article | Graphical Abstract

Restraining FOXO3-Dependent Transcriptional BMF Activation Underpins Tumor Growth and Metastasis of E-Cadherin-Negative Breast Cancer
Researchers report that E-cadherin inactivation in breast cancer cells induces PI3K/AKT-dependent FOXO3 inhibition and identified FOXO3 as a novel and direct transcriptional activator of the pro-apoptotic protein BMF. [Cell Death Differ] Abstract

Trastuzumab-Grafted PAMAM Dendrimers for the Selective Delivery of Anticancer Drugs to HER2-Positive Breast Cancer
Scientists synthesized trastuzumab-grafted dendrimers to improve delivery of docetaxel to human epidermal growth factor receptor 2 (HER2)-positive breast cancer cells. [Sci Rep] Full Article

Doxorubicin Resistant Cancer Cells Activate Myeloid-Derived Suppressor Cells by Releasing PGE2
Researchers used in vitro cell culture and in vivo animal studies to demonstrate that doxorubicin-resistant breast cancer cells secrete significantly more prostaglandin E2 (PGE2) than their parental doxorubicin-sensitive cells. [Sci Rep] Full Article

Targeting the Epigenetics of the DNA Damage Response in Breast Cancer
Investigators proposed an adjuvant therapy that targets the epigenetics of the DNA damage response in breast cancer cells and that results in efficient apoptosis and a reduction in distant metastases in vivo. [Cell Death Dis] Full Article

The Bag-1 Inhibitor, Thio-2, Reverses an Atypical 3D Morphology Driven by Bag-1L Overexpression in a MCF-10A Model of Ductal Carcinoma In Situ
Scientists examined whether the nuclear Bcl-2-associated athanogene 1 (Bag-1) isoform is sufficient to drive premalignant change by developing a Bag-1L-overexpressing MCF-10A model. Two clones differentially overexpressing Bag-1L were grown in two-dimensional and three-dimensional cultures and compared with an established model of HER2-driven transformation. [Oncogenesis] Full Article

MicroRNA-206 Is Differentially Expressed in Brca1-Deficient Mice and Regulates Epithelial and Stromal Cell Compartments of the Mouse Mammary Gland
Researchers examined the mammary glands of MMTV-Cre Brca1^Co/Co mice for differential miRNA expression using a candidate approach. Several miRNAs were differentially expressed in mammary tissue at day one of lactation and in mammary epithelial cell lines in which Brca1 messenger RNA levels have been reduced. [Oncogenesis] Full Article

CLINICAL RESEARCH

Bevacizumab Plus Neoadjuvant Chemotherapy in Patients with HER2-Negative Inflammatory Breast Cancer (BEVERLY-1): A Multicenter, Single-Arm, Phase II Study
In the BEVERLY-1 trial researchers aimed to assess the addition of bevacizumab to neoadjuvant and adjuvant chemotherapy in the treatment of patients with HER2-negative inflammatory breast cancer. [Lancet Oncol] Abstract

Primary Analysis of a Prospective, Randomized, Single-Blinded Phase II Trial Evaluating the HER2 Peptide AE37 Vaccine in Breast Cancer Patients to Prevent Recurrence
Phase I studies showed AE37 administered with granulocyte macrophage colony-stimulating factor to be safe and highly immunogenic. A prospective, randomized, multicenter Phase II adjuvant trial was conducted to evaluate the vaccine’s efficacy. [Ann Oncol] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

From our sponsor: 3D intestinal organoid culture is made easy with IntestiCult™. Request a sample.

American Cancer Society Awards New Research and Training Grants
The American Cancer Society has approved funding for 103 research and training grants totaling nearly $44 million in the first of two grant cycles for 2016. [The American Cancer Society] Press Release

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the mammary cell community.

NEW Faculty Position – Cancer Research (Eppley Institute for Research in Cancer)

NEW Postdoctoral Fellow – Breast Cancer (Northwestern Universtiy)

Faculty Position – Tumor Immunology (John Wayne Cancer Institute at Providence Saint John’s Health Center)

Postdoctoral Fellow – Noncoding RNAs in Breast Cancer (University of Texas MD Anderson Cancer Center)

Postdoctoral Fellow – Breast and Ovarian Cancer (Johns Hopkins University School of Medicine)

PhD Fellowship – Breast Cancer (INCLIVA Health Research Institute)

Postdoctoral Fellowship – Platelets in Metastatic Breast and Colon Cancer (Université de Strasbourg)

Research Associate – Breast Cancer and Huntington’s Disease (University of Pittsburgh Drug Discovery Institute)

Postdoctoral Fellowship – Tumor Biology of Breast and Lung Cancer (Cold Spring Harbor Laboratory)

Postdoctoral Fellowship – Microenvironment of Breast Cancer (Icahn School of Medicine)

Postdoctoral Fellowship – Breast and Prostate Cancer Molecular Mechanisms (Feinberg School of Medicine)

Postdoctoral Fellowship – Epigenetic Reprogramming of Breast Cancer Stem Cells (University of Toronto)

Postdoctoral Fellowship – Various Projects in Cancer Biology (National University of Singapore)

Postdoctoral Fellowship – Genetic and Epigenetic Variability in Breast Cancer (The University of Tennessee Health Science Center)

Manager – Medical and Breast Imaging (Fred Hutchinson Cancer Research Center)

Clinical Pathways Associate – Cancer Therapeutics (Fred Hutchinson Cancer Research Center)

Director Clinical Research – Medical Oncology (Fred Hutchinson Cancer Research Center)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.